NO300217B1 - Fremgangsmåte for isolering og rensing av bovin eller human G-CSF fra en mikroorganisme som produserer bovin eller human G-CSF - Google Patents

Fremgangsmåte for isolering og rensing av bovin eller human G-CSF fra en mikroorganisme som produserer bovin eller human G-CSF Download PDF

Info

Publication number
NO300217B1
NO300217B1 NO900185A NO900185A NO300217B1 NO 300217 B1 NO300217 B1 NO 300217B1 NO 900185 A NO900185 A NO 900185A NO 900185 A NO900185 A NO 900185A NO 300217 B1 NO300217 B1 NO 300217B1
Authority
NO
Norway
Prior art keywords
csf
bovine
human
mastitis
animals
Prior art date
Application number
NO900185A
Other languages
English (en)
Norwegian (no)
Other versions
NO900185L (no
NO900185D0 (no
Inventor
Thomas C Boone
Allan L Miller
Jeffrey W Andresen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO900185D0 publication Critical patent/NO900185D0/no
Publication of NO900185L publication Critical patent/NO900185L/no
Publication of NO300217B1 publication Critical patent/NO300217B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Filling Or Discharging Of Gas Storage Vessels (AREA)
NO900185A 1988-05-13 1990-01-12 Fremgangsmåte for isolering og rensing av bovin eller human G-CSF fra en mikroorganisme som produserer bovin eller human G-CSF NO300217B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19385788A 1988-05-13 1988-05-13
US34801189A 1989-05-09 1989-05-09
PCT/US1989/002057 WO1989010932A1 (en) 1988-05-13 1989-05-12 Compositions and method for treating or preventing infections in animals

Publications (3)

Publication Number Publication Date
NO900185D0 NO900185D0 (no) 1990-01-12
NO900185L NO900185L (no) 1990-03-12
NO300217B1 true NO300217B1 (no) 1997-04-28

Family

ID=26889429

Family Applications (1)

Application Number Title Priority Date Filing Date
NO900185A NO300217B1 (no) 1988-05-13 1990-01-12 Fremgangsmåte for isolering og rensing av bovin eller human G-CSF fra en mikroorganisme som produserer bovin eller human G-CSF

Country Status (12)

Country Link
US (1) US5849883A (da)
EP (2) EP0347041A3 (da)
JP (1) JP2796388B2 (da)
KR (1) KR0133561B1 (da)
AT (1) ATE452190T1 (da)
AU (3) AU636127B2 (da)
DE (1) DE68929566D1 (da)
DK (1) DK175245B1 (da)
FI (1) FI900178A7 (da)
NO (1) NO300217B1 (da)
NZ (1) NZ229098A (da)
WO (1) WO1989010932A1 (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
JP2796388B2 (ja) 1988-05-13 1998-09-10 アムジエン・インコーポレーテツド Ｇ−ｃｓｆの精製方法
EP0648501A1 (en) * 1989-10-10 1995-04-19 Amgen Inc. Compositions comprising G-CSF for treating or preventing infections in canine and feline animals
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
WO1996006170A1 (en) * 1994-08-19 1996-02-29 Embrex, Inc. Method of treating birds with avian myelomonocytic growth factor
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
ES2216447T3 (es) * 1998-08-17 2004-10-16 Pfizer Products Inc. Composiciones proteicas estabilizadas.
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
PT1129720E (pt) 2000-02-29 2004-08-31 Pfizer Prod Inc Factor estimulador de colonias de granulocitos estabilizado
JP4799803B2 (ja) * 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
PL371781A1 (en) 2001-07-11 2005-06-27 Maxygen Holdings, Ltd. G-csf conjugates
SI21102A (sl) * 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
US7557195B2 (en) 2002-03-20 2009-07-07 Biopolymed, Inc. Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
AU2002345829A1 (en) * 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
EP1641484A2 (en) * 2003-05-09 2006-04-05 Schering Aktiengesellschaft Treatment of inflammatory respiratory diseases
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
RU2385878C2 (ru) 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
EP2631244A1 (en) 2004-10-08 2013-08-28 Amylin Pharmaceuticals, Inc. Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
MX2007006830A (es) 2004-12-13 2008-02-07 Amylin Pharmaceuticals Inc Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
EP1888119B1 (en) 2005-06-01 2011-03-09 Maxygen, Inc. Pegylated g-csf polypeptides and methods of producing same
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US9176145B2 (en) 2006-07-21 2015-11-03 Femalon S.P.R.L. Kit for predicting implantation success in assisted fertilization
WO2008116470A1 (en) * 2007-03-26 2008-10-02 Drugrecure Aps Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor
DE202008017456U1 (de) 2007-08-27 2009-08-27 Biogenerix Ag Flüssig-Formulierung von G-CSF-Konjugaten
CN102089319B (zh) 2008-05-08 2013-11-13 味之素株式会社 蛋白质的重折叠方法
PT2318029T (pt) * 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EA020621B1 (ru) 2009-06-22 2014-12-30 Амген Инк. Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
LT3660032T (lt) 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
MX2012010661A (es) 2010-03-17 2013-03-25 Biogenerix Gmbh Metodo para obtener factor estimulante de colonias de granulocitos (g-csf) humano recombinante biologicamente activo.
RU2487885C2 (ru) * 2010-07-20 2013-07-20 Зао "Биокад" Способ крупномасштабного получения, выделения и очистки рекомбинантного гранулоцитарного колониестимулирующего фактора человека
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
HUP1200172A2 (en) * 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
EP2855517A1 (en) 2012-05-29 2015-04-08 Novo Nordisk A/S Pancreatic polypeptide compounds and use
WO2014155349A2 (en) 2013-03-29 2014-10-02 Dr. Reddy's Laboratories Refolding of proteins
WO2019075053A1 (en) * 2017-10-11 2019-04-18 Elanco Us Inc. PORCINE G-CSF VARIANTS AND USES THEREOF
WO2020234742A1 (en) * 2019-05-20 2020-11-26 Lupin Limited Granulocyte colony stimulating factor purification
WO2021007243A1 (en) * 2019-07-09 2021-01-14 Tanvex Biopharma Usa, Inc. Temperature-controlled purification of granulocyte-colony stimulating factor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2438821A1 (fr) * 1978-10-13 1980-05-09 France Etat Dispositif d'allumage a fil chaud de securite
US4618600A (en) * 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
JPS6145010A (ja) * 1984-08-08 1986-03-04 Setsuji Umezaki 埋立地の造成方法
JPH0615477B2 (ja) * 1985-02-08 1994-03-02 中外製薬株式会社 感染防禦剤
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4721420A (en) * 1985-09-03 1988-01-26 Arthur D. Little, Inc. Pipeline transportation of coarse coal-liquid carbon dioxide slurry
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
AU621051B2 (en) * 1987-04-28 1992-03-05 Amgen, Inc. Method for purifying granulocyte-macrophage colony stimulating factor
EP0313343B2 (en) * 1987-10-23 2003-07-23 Schering Corporation Method of purifying protein
JP2796388B2 (ja) 1988-05-13 1998-09-10 アムジエン・インコーポレーテツド Ｇ−ｃｓｆの精製方法

Also Published As

Publication number Publication date
FI900178A0 (fi) 1990-01-12
JPH02504521A (ja) 1990-12-20
NO900185L (no) 1990-03-12
AU4781290A (en) 1990-11-15
WO1989010932A1 (en) 1989-11-16
EP0719860A1 (en) 1996-07-03
KR0133561B1 (ko) 1998-04-21
US5849883A (en) 1998-12-15
DE68929566D1 (de) 2010-01-28
FI900178A7 (fi) 1990-01-12
NO900185D0 (no) 1990-01-12
JP2796388B2 (ja) 1998-09-10
EP0719860B1 (en) 2009-12-16
AU636127B2 (en) 1993-04-22
NZ229098A (en) 1992-10-28
EP0347041A3 (en) 1990-11-22
KR900701824A (ko) 1990-12-04
DK175245B1 (da) 2004-07-19
ATE452190T1 (de) 2010-01-15
AU4197393A (en) 1993-10-28
AU661172B2 (en) 1995-07-13
AU4197293A (en) 1993-10-28
EP0347041A2 (en) 1989-12-20
DK9290D0 (da) 1990-01-12
DK9290A (da) 1990-03-09

Similar Documents

Publication Publication Date Title
NO300217B1 (no) Fremgangsmåte for isolering og rensing av bovin eller human G-CSF fra en mikroorganisme som produserer bovin eller human G-CSF
Hoeben et al. Role of endotoxin and TNF-α in the pathogenesis of experimentally induced coliform mastitis in periparturient cows
JPH04502164A (ja) 犬科・猫科動物における感染の治療または予防のための化学組成物及び方法
MXPA03007672A (es) Metodo para mejorar la funcion de crecimiento de un animal.
JP2010059167A (ja) 免疫原性ｌｈｒｈ組成物およびそれに関する方法
US12286462B2 (en) Porcine G-CSF variants and their uses
FI103342B (fi) Menetelmä G-CSF:n eristämiseksi ja puhdistamiseksi
CA1341405C (en) Methods of isolation and purification of g-csf
JP4629964B2 (ja) ウシの消化器疾患治療剤
CA3077215C (en) Porcine g-csf variants and their uses
RU2823074C2 (ru) Варианты свиного g-csf и их применение
RU2765287C1 (ru) Способ повышения колострального иммунитета и неспецифической резистентности у телят
CN100998873B (zh) 一种防治动物乳房炎的基因药物
KR20250017207A (ko) 돼지에서의 항염증성 분자의 비치료적 용도
JPWO2007037098A1 (ja) 繁殖障害改善剤
JPH10505232A (ja) 鳥類骨髄単球性成長因子を用いる鳥類の処置方法
JP2010189448A (ja) ウシの消化器疾患治療剤

Legal Events

Date Code Title Description
MK1K Patent expired